BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock
Key stats
- Market cap
- $205.44M
- Price / Earnings ratio
- -1.0x
- EPS (TTM)
- -$1230.15
- Volume
- Loading
- 52-week high
- $14.87
- 52-week low
- $1.98
Source: third-party data provider, as of November 13, 2026
Compare with BBOT
Technical indicators
- RSI 14
- 40.05
- MACD 12/26/9
- -0.47
- EMA 9 of MACD
- -0.56
- MACD histogram
- 0.10
- SMA 50
- $3.92
- Price below SMA 50
- EMA 50
- $3.93
- Price below EMA 50
- SMA 200
- $7.75
- Price below SMA 200
- EMA 200
- $7.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
About BridgeBio Oncology Therapeutics, Inc. Common Stock
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Executive Officer and Director | 1971 |
| Dr. Neil Kumar Ph.D. | Executive Chairman | 1979 |
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Non-Executive Director & Chair of the Advisory Board | 1950 |
| Mr. Idan Elmelech M.A., M.B.A. | Chief Operating Officer | 1993 |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical & Development Officer | 1974 |
| Mr. Marc Cobo | VP of Finance & Controller | 1981 |
| Mr. Aaron Chan J.D. | Vice President of Legal | — |
| Mr. Bin Wang Ph.D. | Senior Vice President of Drug Discovery | — |
| Mr. Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls | — |
| Mr. Rui Xu Ph.D. | Senior Vice President of Drug Discovery | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 40.05
- MACD 12/26/9
- -0.47
- EMA 9 of MACD
- -0.56
- MACD histogram
- 0.10
- SMA 50
- $3.92
- Price below SMA 50
- EMA 50
- $3.93
- Price below EMA 50
- SMA 200
- $7.75
- Price below SMA 200
- EMA 200
- $7.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $17.78
- High
- $27.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.3 | +6.9 | -10.9 | +3.7 | +6.7 | -53.5 | -33.5 | +10.8 |




